Liraglutide Improves Forced Vital Capacity in Individuals With Type 2 Diabetes: Data From the Randomized Crossover LIRALUNG Study.

Carolina López-Cano, Andreea Ciudin, Enric Sánchez, Francisco J Tinahones, Ferran Barbé, Mireia Dalmases, Marta García-Ramírez, Alfonso Soto, Anna Michela Gaeta, Silvia Pellitero, Raquel Martí, Cristina Hernández, Rafael Simó, Albert Lecube

Journal: Diabetes 2022;71(2):315-320

PMID: 34737187

Free Full Text on Andalusian Health Repository - access to free full text View on PubMed

Abstract

To evaluate the effect of liraglutide, a glucagon-like peptide 1 receptor agonist, on pulmonary function and serum levels of surfactant protein D (SP-D) in type 2 diabetes. A double-blind, randomized, crossover, placebo-controlled clinical trial comprising 76 patients with a baseline forced expiratory volume in 1 s <90% of that predicted. Liraglutide was administered for 7 weeks (2 weeks of titration plus 5 weeks at 1.8 mg daily). This short duration was intentional to minimize weight loss as a potential confounding factor. Serum level of SP-D was used as a biomarker of alveolar-capillary barrier integrity. Liraglutide exerted a positive impact on forced vital capacity (FVC) in comparison with placebo (ΔFVC 5.2% of predicted [from 0.8 to 9.6]; P = 0.009). No differences in the other pulmonary variables were observed. Participants under liraglutide treatment also experienced a decrease in serum SP-D (P = 0.038). The absolute change in FVC correlated with final serum SP-D in participants receiving liraglutide (r = -0.313, P = 0.036). Stepwise multivariate regression analysis showed that final serum SP-D independently predicted changes in FVC. In conclusion, liraglutide increased FVC in patients with type 2 diabetes. This effect was associated with a significant decrease of circulating SP-D, thus pointing to a beneficial effect in the alveolar-capillary function.

Address: Endocrinology and Nutrition Department, Hospital Universitari Arnau de Vilanova, and Obesity, Diabetes and Metabolism Research Group, Institut de Recerca Biomèdica de Lleida, Universitat de Lleida. Lleida, Spain.; Endocrinology and Nutrition Department. Hospital Universitari Vall d'Hebron, and Diabetes and Metabolism Research Unit, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.; Endocrinology and Nutrition Department, Hospital Universitario Virgen de la Victoria de Málaga, Institute of Biomedical Research of Malaga, University of Malaga, Málaga, Spain.; Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.; Respiratory Department, Hospital Universitari Arnau de Vilanova-Santa María, and Translational Research in Respiratory Medicine, Institut de Recerca Biomèdica de Lleida, Universitat de Lleida. Lleida, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.; Endocrinology and Nutrition Department, Hospital Universitario A Coruña, A Coruña, Spain.; Department of Endocrinology and Nutrition, Hospital Universitari Germans Trias i Pujol, Germans Trias i Pujol Research Institute, Badalona, Spain.

DOI: 10.2337/db21-0688

Link outs

Free resources

Full Text Sources:

http://hdl.handle.net/10668/20499

Medical:

Subscription / membership required

Full Text Sources:

MeSH Terms: Aged, Blood Glucose, Cross-Over Studies, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycemic Control, Humans, Liraglutide, Lung, Male, Middle Aged, Pulmonary Surfactant-Associated Protein D, Spain, Vital Capacity